Form 4: Apogee Therapeutics Director Receives Stock Option Grant

Director Jennifer A. Fox was granted 7,657 stock options in Apogee Therapeutics, Inc. as disclosed in a recent SEC Form 4 filing.

Summary

• Director Jennifer A. Fox received a grant of 7,657 stock options for Apogee Therapeutics, Inc. (APGE) common stock.
• The options have an exercise price of $85.00 per share.
• The grant was issued on June 9, 2026, and is set to expire on June 9, 2036.
• The options are subject to a one-year vesting schedule, contingent upon continued service to the company.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation with no immediate impact on company operations or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is contingent upon the director's continued service to the issuer.

Future Outlook

The options vest on the one-year anniversary of the grant date, June 9, 2027, provided the director remains in service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure long-term alignment with company performance.

Comparison to Industry Standards

• The use of stock options for director compensation is consistent with standard practices for mid-cap biotechnology firms.
• Vesting schedules of one year for director equity are common in the industry to balance retention and performance incentives.

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of the 7,657 stock options on June 9, 2027.

Key Dates

Keywords

Apogee Therapeutics, APGE, Form 4, Insider Trading, Stock Options, Director Compensation